Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Acorda Therapeutics Inc. -- Ignore unavailable to you. Want to Upgrade?

To: kenhott who wrote (35)	8/4/2009 12:41:57 PM
From: Arthur Radley	Read Replies (1) \| Respond to of 120

Meanwhile, the company reported updated side-effect information from the Fampridine program. The key change is the relapse rate in patients. The data show that 5.3 percent of patients taking Fampridine-SR relapsed while only 3.8 percent taking a placebo relapsed. But, the relapses occurred after patients discontinued treatment with Fampridine, Acorda said. Analysts were mixed on how the new information will affect the upcoming FDA panel meeting. Leerink Swann analyst Dr. Joshua Schimmer said the explanation that relapses occurred after patients stopped taking the drug could actually benefit Fampridine-SR. "If anything, it reinforces the view that Fampridine-SR has relevant clinical activity since withdrawing the drug is perceived as a negative event by patients," he said in a note to investors, reaffirming a "Outperform" rating. Meanwhile, Deutsche Bank-North America analyst Mark Schoenebaum remained cautious, but optimistic following the results, saying the new data are "slightly worrisome." He reaffirmed a "Buy" rating on the stock.